Mesoblast (NASDAQ:MESO) was downgraded by Zacks Investment Research from a "buy" rating to a "hold" rating in a report released on Wednesday, Zacks.com reports.
According to Zacks, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. "
A number of other brokerages have also recently weighed in on MESO. ValuEngine upgraded Mesoblast from a "hold" rating to a "buy" rating in a report on Thursday, April 2nd. Maxim Group started coverage on Mesoblast in a research note on Friday, May 29th. They issued a "buy" rating and a $16.00 price objective for the company. LADENBURG THALM/SH SH upped their target price on shares of Mesoblast from $13.00 to $15.25 and gave the stock a "buy" rating in a research note on Thursday, May 28th. TheStreet raised shares of Mesoblast from a "d+" rating to a "c-" rating in a report on Friday, May 22nd. Finally, HC Wainwright reiterated a "buy" rating and set a $21.00 price target (up previously from $14.00) on shares of Mesoblast in a report on Thursday, May 28th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of "Buy" and a consensus target price of $14.91.
Our Technical Analysis Guide will give you the insight into todays fast-moving markets. Its designed to give you a head start in learning the basics of various TA tools and techniques.
NASDAQ:MESO opened at $13.39 on Wednesday. The company has a market capitalization of $1.49 billion, a P/E ratio of -20.92 and a beta of 3.53. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.15. Mesoblast has a 52 week low of $3.12 and a 52 week high of $20.57. The stock's fifty day moving average is $10.75 and its two-hundred day moving average is $8.08.
Mesoblast (NASDAQ:MESO) last announced its earnings results on Wednesday, May 27th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.14). Mesoblast had a negative return on equity of 13.60% and a negative net margin of 197.65%. The company had revenue of $12.20 million for the quarter, compared to analyst estimates of $9.38 million. Sell-side analysts anticipate that Mesoblast will post -0.57 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tobias Financial Advisors Inc. acquired a new stake in Mesoblast during the 4th quarter worth $191,000. Wilbanks Smith & Thomas Asset Management LLC boosted its stake in shares of Mesoblast by 6.0% during the fourth quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 25,025 shares of the company's stock worth $184,000 after buying an additional 1,425 shares during the period. Ingalls & Snyder LLC acquired a new stake in shares of Mesoblast during the first quarter worth about $53,000. Aperio Group LLC purchased a new position in shares of Mesoblast during the first quarter worth about $81,000. Finally, Cetera Advisor Networks LLC acquired a new position in Mesoblast in the 1st quarter valued at about $44,000. 2.12% of the stock is currently owned by institutional investors.
Mesoblast Company Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Further Reading: Hedge Funds Explained
Get a free copy of the Zacks research report on Mesoblast (MESO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [emailprotected]
13 Stocks Institutional Investors Won't Stop Buying
University endowments, pension funds, sovereign wealth funds, hedge funds and other institutional investors have recently been pouring money into a a group of 13 elite stocks.
These institutional investors don't get easily swayed by hot stocks that are popular with retail investors. You probably won't see a Tesla or a SnapChat in this group, because institutional investors know that these "popular kid" stocks almost always aren't great investments. However, you will find some incredibly solid companies on this list backed by real earnings and real fundamentals.
In order to identify these stocks, we had to comb through every 13D and 13F filing that institutional investors have filed with the SEC in the last quarter. After reviewing more than 5,000 filings, we have identified 13 companies that institutional investors have been buying left. Big money investors are pouring hundreds of millions of dollars into these stocks.
View the "13 Stocks Institutional Investors Won't Stop Buying".
- This revolutionary new coronavirus cure is already saving lives - BGR - August 14th, 2020
- Survivors of Pediatric Cancers May Experience Lasting Impact on Heart, Metabolic Health Following Radiation Therapy - Pharmacy Times - August 14th, 2020
- TG Therapeutics Umbralisib Development, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha - August 14th, 2020
- Stem Cell And Regenerative Therapy Market Industry Outlook, Growth Prospects and Key Opportunities - Kentucky Journal 24 - August 13th, 2020
- Radiation to treat pediatric cancers may have lasting impact on heart and metabolic health - Science Codex - August 13th, 2020
- Opportunities in the Global Induced Pluripotent Stem Cell (iPS Cell) Industry - PRNewswire - August 11th, 2020
- Human Embryonic Stem Cells market to see major growth by 2026 | Lonza Group Ltd., Life Technologies Corporation, NuVasive Inc., TiGenix NV, Sumanas,... - August 11th, 2020
- Stem Cell Banking Market Industry Analysis & Forecast (2019-2026) by Type, Service, Application and Geography. - Good Night, Good Hockey - August 11th, 2020
- Salles Speaks to the Potential Benefit of the Tafasitamab Combo in the R/R DLBCL Setting - Targeted Oncology - August 10th, 2020
- Stem Cell And Regenerative Therapy Market: Global Forecast over COVID-19 2024 - eRealty Express - August 10th, 2020
- Edited Transcript of ALLO.OQ earnings conference call or presentation 5-Aug-20 12:30pm GMT - Yahoo Finance - August 6th, 2020
- Edited Transcript of XNCR.OQ earnings conference call or presentation 4-Aug-20 8:30pm GMT - Yahoo Finance - August 5th, 2020
- Global Adrenoleukodystrophy Treatment Trends and Highlights - Bulletin Line - August 4th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027)-by Sources, Cell Type, Application, End User and Region. - WOLE TV - August 3rd, 2020
- Stem Cell Reconstructive Market Will Reflect Significant Growth Prospects of US$ Mn during 2020-2025 with Major Key Player: NuVasive, Cytori... - July 30th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027)-by Sources, Cell Type, Application, End User and Region. - Red... - July 30th, 2020
- Orthopedic Regenerative Medicine Market Insights and Business Outlook By Top Players Curasan, Inc., Carmell Therapeutics Corporation, Anika... - July 29th, 2020
- Books: Five new books to read this week - HeraldScotland - July 29th, 2020
- Orthopedic Regenerative Medicine Market Research Report 2020 Overall Analysis and Forecast up to the Year 2027 - Sanford Philosopher - July 28th, 2020
- BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update - Yahoo Finance - July 27th, 2020
- New Study Offers First Glimpse Into How Widespread COVID-19 Antibodies are in Canada's Adult Population - Canada NewsWire - July 24th, 2020
- US regulations for regenerative medicine advanced therapies - Regulatory Focus - July 24th, 2020
- Scientists discovered the real reason behind goosebumps - Tech Explorist - July 24th, 2020
- Study finds the real reason you get goosebumps - Big Think - July 24th, 2020
- Stem Cell Therapy Market to Surpass US$ 40.3 Billion by 2027, Owing to Increasing Incidence of Spina - PharmiWeb.com - July 24th, 2020
- Celltex Therapeutics Webinar | Houston, TX Patch - Patch.com - July 23rd, 2020
- New study offers first glimpse into how widespread COVID-19 antibodies are in Canada's adult population - McGill Newsroom - July 23rd, 2020
- Data Shows Direct Link Between COVID-19 and Acute Respiratory Distress Syndrome (ARDS) In Infected P - PharmiWeb.com - July 22nd, 2020
- The global cell expansion market size is estimated to be USD 14.9 billion in 2020 and projected to reach USD 30.1 billion by 2025, at a CAGR of 15.1%... - July 22nd, 2020
- Charles Darwin Investigated Goosebumps Now Harvard Scientists Discover the Real Reason Behind Them - SciTechDaily - July 21st, 2020
- Higher Steaks Creates World's First Lab-Grown Bacon and Pork Belly - The Spoon - July 21st, 2020
- Stem Cells Market Analysis Growth Opportunities and Demand Drives by 2016 to 2028 - Jewish Life News - July 19th, 2020
- Local scientists create 'mini livers' to trial therapies for liver diseases - The Straits Times - July 17th, 2020
- Can banking your stem cells prevent aging? | Well+Good - July 16th, 2020
- Expected Growth In Stem Cells Market from 2020-2026 to Guide : Trends, Analysis by Manufacturers, Regions, Type and Application - Owned - July 16th, 2020
- The Baxter Foundation supports USC research on epilepsy and lung injury - USC News - July 16th, 2020
- Adult Stem Cell Success Story Leukemia | BRMS - July 16th, 2020
- Researchers find that fish oil may help with depression - Jill Lopez - July 15th, 2020
- Induced Pluripotent Stem Cells Market Outlook With Key Player, Regions, CAGR of 12.2%, and Specification, Cost Analysis, Price and Gross Margin by... - July 15th, 2020
- COVID-19 Analysis | Canine Stem Cell Therapy Market by Trends, Dynamic Innovation in Technology and 2026 Forecasts - 3rd Watch News - July 14th, 2020
- Cortical Bone Derived Stem Cells Modulate Cardiac Fibroblast Response via miR-18a in the Heart After Injury - DocWire News - July 14th, 2020
- Cord blood banking in Bulgaria: problems of control and continuing insurance - Lexology - July 13th, 2020
- 13 promising Covid-19 treatments emerging from Israel - The Yucatan Times - July 10th, 2020
- Stem Cell Manufacturing Market Outlook, Opportunity and Demand Analysis, Forecast 2020-2027|-Merck Group, Becton, Dickinson And Company. Holostem... - July 10th, 2020
- Biopreservation Market 2020 Global Analysis, Size, Growth, Covid-19 Impact Analysis, Leading Players, Merger, Acquisition, Opportunity, With Regional... - July 10th, 2020
- Cellular Reprogramming Tools Market Key Players, Industry Overview, Application and Analysis to 2020-2026 - Cole of Duty - July 2nd, 2020
- Growth in Sales of Cell Banking Outsourcing Market to Push Revenue Growth in the Market - 3rd Watch News - July 2nd, 2020
- COVID-19: Plasma therapy vs stem cell therapy, what's the difference? - Gulf News - June 29th, 2020
- Label-free sensing of exosomal MCT1 and CD147 for tracking metabolic reprogramming and malignant progression in glioma - Science Advances - June 29th, 2020
- Novel coronavirus infection might trigger type-1 diabetes - The Hindu - June 29th, 2020
- Stem Cells Market Analysis Growth Opportunities and Demand Drives by 2016 to 2028 - 3rd Watch News - June 28th, 2020
- BrainStorm Cell Therapeutics to Join the Russell 2000 Index and Russell 3000 Index - Yahoo Finance - June 26th, 2020
- COVID-19 impact: Stem Cells Market to Witness Steady Expansion During 2019-2026 - Personal Injury Bureau UK - June 26th, 2020
- Nuclear softening expedites interstitial cell migration in fibrous networks and dense connective tissues - Science Advances - June 20th, 2020
- Global Stem Cell Market Study and Forecast 2020-2025: Oncology Disorders Expected to Exhibit the Fastest Growth Rate - ResearchAndMarkets.com -... - June 20th, 2020
- EHA25Virtual: Adult Patients With Sickle Cell Disease May Be at Increased Risk of Adverse Outcomes From COVID-19 - Yahoo Finance - June 16th, 2020
- Tolero Pharmaceuticals Presents Findings from Phase 1 Zella 101 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Newly... - June 16th, 2020
- Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress - BioSpace - June 12th, 2020
- Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX (daratumumab) for the Treatment of Patients with Multi... - June 12th, 2020
- Having a good level of vitamin D may reduce the risk of certain cancers - Yahoo Singapore News - June 11th, 2020
- Major skin cancer research study to begin at The Hormel Institute - Austin Daily Herald - Austin Herald - June 11th, 2020
- Transforming the spleen into a liver-like organ in vivo - Science Advances - June 11th, 2020
- Creating hairy human skin: Not as easy as you think - Science Codex - June 7th, 2020
- Cellular Reprogramming Tools Market Research Key Players, Industry Overview and forecasts to | 2026 - Weekly Wall - June 5th, 2020
- Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX (daratumumab) for the Treatment of Patients with... - June 5th, 2020
- Follica Announces Positive Feedback From End of Phase 2 Meeting With FDA for Its Lead Program to Treat Male Androgenetic Alopecia - Business Wire - June 5th, 2020
- Global Stem Cell Characterization Kits Market : Analysis and In-depth Study on Market Size Trends, Emerging Growth Factors and Forecasts to 2029 - The... - June 3rd, 2020
- Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 - WhaTech Technology and Markets News - June 2nd, 2020
- AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other... - June 2nd, 2020
- Stem Cell Assay Market to Witness Growth Acceleration During 2017-2025 - Cole of Duty - June 2nd, 2020
- Study reveals birth defects caused by flame retardant - University of Georgia - June 2nd, 2020
- What It's Like to Grow a 'Mini-Brain' From Your Own Cells - Discover Magazine - May 25th, 2020
- Canine Stem Cell Therapy Market Covid-19 Impact In 2026 | In-depth Analysis, Global Market Share, Top Trends, Professional & Technical Industry... - May 25th, 2020
- Newborn in Japan receives first treatment with liver STEM cells - ZME Science - May 23rd, 2020
- Adult Stem Cells Market with Coronavirus (Covid-19) Impact Analysis | Industry Strong Development By Major Eminent Players, New Innovations, Key... - May 16th, 2020
- Stem Cell and Regenerative Therapy Market Covid-19 Impact Analysis, Size, Share & Trends Analysis Report by Component, By Enterprise Size, By End... - May 16th, 2020
- The RNA binding protein CPEB2 regulates hormone sensing in mammary gland development and luminal breast cancer - Science Advances - May 16th, 2020
- Stem Cells Market Market Developments and Analysis (impact of Covid-19) 2020-2026 - Herald Writeup - May 15th, 2020
- Takeda Pharmaceutical : China announces ADCETRIS (brentuximab vedotin) is approved for the treatment of adult patients with CD30-positive Lymphomas -... - May 15th, 2020
- New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European... - May 14th, 2020